As of 2025-05-26, the Intrinsic Value of AFT Pharmaceuticals Ltd (AFT.NZ) is 3.89 NZD. This AFT.NZ valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 2.78 NZD, the upside of AFT Pharmaceuticals Ltd is 40.00%.
The range of the Intrinsic Value is 2.69 - 7.08 NZD
Based on its market price of 2.78 NZD and our intrinsic valuation, AFT Pharmaceuticals Ltd (AFT.NZ) is undervalued by 40.00%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 2.69 - 7.08 | 3.89 | 40.0% |
| DCF (Growth 10y) | 3.89 - 9.87 | 5.54 | 99.4% |
| DCF (EBITDA 5y) | 4.07 - 6.42 | 5.14 | 84.8% |
| DCF (EBITDA 10y) | 4.92 - 8.11 | 6.32 | 127.3% |
| Fair Value | 2.77 - 2.77 | 2.77 | -0.47% |
| P/E | 2.43 - 8.81 | 4.49 | 61.6% |
| EV/EBITDA | 1.90 - 3.40 | 2.60 | -6.6% |
| EPV | 1.18 - 1.72 | 1.45 | -47.8% |
| DDM - Stable | 0.94 - 3.20 | 2.07 | -25.6% |
| DDM - Multi | 2.67 - 7.06 | 3.88 | 39.5% |
| Market Cap (mil) | 291.54 |
| Beta | 0.37 |
| Outstanding shares (mil) | 104.87 |
| Enterprise Value (mil) | 314.49 |
| Market risk premium | 5.10% |
| Cost of Equity | 8.67% |
| Cost of Debt | 5.00% |
| WACC | 8.16% |